<DOC>
	<DOC>NCT01543724</DOC>
	<brief_summary>The investigators will assess Li-induced gray matter volume changes with regard to the endophenotype of GSK3beta polymorphism. The changes of gray matter are supposed to be more attributable to neurotrophic and neuroprotective characteristics of Li, which were closely related to the inhibition of apoptotic activity of GSK3beta.</brief_summary>
	<brief_title>Neural Correlates for Therapeutic Mechanisms of Lithium in Bipolar Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>Men and Women aged between 19 and 55 Diagnosis of bipolar I disorder as assessed by the structured clinical interview for DSMIV (SCIDIV) Patients who have not used psychoactive medications for more than 2 weeks Individuals who provided written consent for participation Presence of any major physical or neurological illness (e.g., head trauma, epilepsy, seizure, stroke, cerebral tumor, multiple sclerosis, cerebrovascular disease, narrowangle glaucoma, drug hypersensitivity, etc.) Women who are pregnant, breastfeeding, or planning pregnancy Diagnosis of any Axis I disorder other than bipolar disorder Intelligence quotient below 80 Current or past drug abuse Contraindications to magnetic resonance imaging (e.g., pacemaker implantation, claustrophobia, etc.)</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>